Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States

被引:7
作者
Varughese, Prateesh [1 ,4 ]
Smith, Robert [1 ]
Xue, Mei [1 ]
Dorrow, Natalie [1 ]
Hogea, Cosmina [2 ]
Maiese, Eric. M. [2 ]
Buckingham, Trudy [3 ]
机构
[1] IntegraConnect, W Palm Beach, FL USA
[2] GlaxoSmithKline, Philadelphia, PA USA
[3] GlaxoSmithKline, Durham, NC USA
[4] IntegraConnect, 501 S Flagler Dr 600, W Palm Beach, FL 33401 USA
关键词
Exposure; options; refractory; retreatment; survival; BELANTAMAB MAFODOTIN; PRECLINICAL ACTIVITY; BISPECIFIC ANTIBODY; GUIDELINES; MANAGEMENT; DIAGNOSIS; EFFICACY; THERAPY;
D O I
10.1080/17474086.2023.2154648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesAlthough multiple myeloma (MM) survival has improved following the introduction of proteosome inhibitors, immunomodulatory drugs, and anti-CD38 therapies, patients become refractory to these agents. Real-world outcomes of triple-class exposed patients are limited and were investigated in this study.MethodsThe Integra Connect Database was used to assess the treatment patterns of triple-class exposed patients with relapsed/refractory MM (RRMM) (January 2016-December 2019).ResultsDuring this period, patients (N = 501) reached triple exposure in a median of three lines of therapy (LOTs) over 995 days. A new LOT was started in a median of 18 (1-691) days after triple exposure; 71% of the patients started a new LOT within 30 days. Throughout the follow-up period, 8% of the patients had a therapy gap greater than 90 days. Following triple exposure, 103/501 patients (21%) received only triple-class agents in subsequent LOTs, while 24 (4.8%) patients received only non-triple-class agents. The median apparent survival from initiation of first therapy after triple exposure was 308 days.ConclusionThese results indicate that recycling of triple-class agents after previous exposure is widespread and prognosis in the RRMM population remains poor, highlighting the continuing unmet need for new agents with novel mechanisms to improve patient outcomes.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 41 条
[1]  
[Anonymous], autolus receives FDA approval for AUCATZYL in adults with relapsed/refractory B-ALL
[2]   Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). [J].
Bahlis, Nizar J. ;
Raje, Noopur S. ;
Costello, Caitlin ;
Dholaria, Bhagirathbhai R. ;
Solh, Melhem M. ;
Levy, Moshe Y. ;
Tomasson, Michael H. ;
Dube, Harman ;
Liu, Feng ;
Liao, Kai Hsin ;
Basu, Cynthia ;
Skoura, Athanasia ;
Chan, Edward Michael ;
Trudel, Suzanne ;
Jakubowiak, Andrzej J. ;
Chu, Michael P. ;
Gasparetto, Cristina ;
Dalovisio, Andrew ;
Sebag, Michael ;
Lesokhin, Alexander M. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3]   Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].
Berdeja, Jesus G. ;
Madduri, Deepu ;
Usmani, Saad Z. ;
Jakubowiak, Andrzej ;
Agha, Mounzer ;
Cohen, Adam D. ;
Stewart, A. Keith ;
Hari, Parameswaran ;
Htut, Myo ;
Lesokhin, Alexander ;
Deol, Abhinav ;
Munshi, Nikhil C. ;
O'Donnell, Elizabeth ;
Avigan, David ;
Singh, Indrajeet ;
Zudaire, Enrique ;
Yeh, Tzu-Min ;
Allred, Alicia J. ;
Olyslager, Yunsi ;
Banerjee, Arnob ;
Jackson, Carolyn C. ;
Goldberg, Jenna D. ;
Schecter, Jordan M. ;
Deraedt, William ;
Zhuang, Sen Hong ;
Infante, Jeffrey ;
Geng, Dong ;
Wu, Xiaoling ;
Carrasco-Alfonso, Marlene J. ;
Akram, Muhammad ;
Hossain, Farah ;
Rizvi, Syed ;
Fan, Frank ;
Lin, Yi ;
Martin, Thomas ;
Jagannath, Sundar .
LANCET, 2021, 398 (10297) :314-324
[4]   Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines [J].
Callander, Natalie S. ;
Baljevic, Muhamed ;
Adekola, Kehinde ;
Anderson, Larry D. ;
Campagnaro, Erica ;
Castillo, Jorge J. ;
Costello, Caitlin ;
Devarakonda, Srinivas ;
Elsedawy, Noura ;
Faiman, Matthew ;
Garfall, Alfred ;
Godby, Kelly ;
Hillengass, Jens ;
Holmberg, Leona ;
Htut, Myo ;
Huff, Carol Ann ;
Hultcrantz, Malin ;
Kang, Yubin ;
Larson, Sarah ;
Liedtke, Michaela ;
Martin, Thomas ;
Omel, James ;
Sborov, Douglas ;
Shain, Kenneth ;
Stockerl-Goldstein, Keith ;
Weber, Donna ;
Berardi, Ryan A. ;
Kumar, Rashmi ;
Kumar, Shaji K. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (01) :9-19
[5]   Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH [J].
Cornell, Robert ;
Hari, Parameswaran ;
Tang, Shijie ;
Biran, Noa ;
Callander, Natalie ;
Chari, Ajai ;
Chhabra, Saurabh ;
Fiala, Mark A. ;
Gahvari, Zhubin ;
Gandhi, Ujjawal ;
Godby, Kelly ;
Gupta, Ridhi ;
Jagannath, Sundar ;
Jagosky, Megan ;
Kang, Yubin ;
Kansagra, Ankit ;
Kauffman, Michael ;
Kodali, Saranya ;
Kumar, Shaji K. ;
Lakshman, Arjun ;
Liedtke, Michaela ;
Lonial, Sagar ;
Ma, Xiwen ;
Malek, Ehsan ;
Mansour, Joshua ;
McGehee, Elizabeth F. ;
Neppalli, Amarendra ;
Paul, Barry ;
Richardson, Paul ;
Scott, Emma C. ;
Shacham, Sharon ;
Shah, Jatin ;
Siegel, David S. ;
Umyarova, Elvira ;
Usmani, Saad Z. ;
Varnado, William ;
Vij, Ravi ;
Costa, Luciano .
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (01) :E5-+
[6]   Diagnosis and Management of Multiple Myeloma A Review [J].
Cowan, Andrew J. ;
Green, Damian J. ;
Kwok, Mary ;
Lee, Sarah ;
Coffey, David G. ;
Holmberg, Leona A. ;
Tuazon, Sherilyn ;
Gopal, Ajay K. ;
Libby, Edward N. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (05) :464-477
[7]   A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells [J].
DiLillo, David J. ;
Olson, Kara ;
Mohrs, Katja ;
Meagher, Thomas Craig ;
Bray, Kevin ;
Sineshchekova, Olga ;
Startz, Thomas ;
Kuhnert, Jessica ;
Retter, Marc W. ;
Godin, Stephen ;
Sharma, Prachi ;
Delfino, Frank ;
Lin, John ;
Smith, Eric ;
Thurston, Gavin ;
Kirshner, Jessica R. .
BLOOD ADVANCES, 2021, 5 (05) :1291-1304
[8]   Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Dimopoulos, M. A. ;
Moreau, P. ;
Terpos, E. ;
Mateos, M., V ;
Zweegman, S. ;
Cook, G. ;
Delforge, M. ;
Hajek, R. ;
Schjesvold, F. ;
Cavo, M. ;
Goldschmidt, H. ;
Facon, T. ;
Einsele, H. ;
Boccadoro, M. ;
San-Miguel, J. ;
Sonneveld, P. ;
Mey, U. .
ANNALS OF ONCOLOGY, 2021, 32 (03) :309-322
[9]   Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial [J].
Facon, Thierry ;
Kumar, Shaji K. ;
Plesner, Torben ;
Orlowski, Robert Z. ;
Moreau, Philippe ;
Bahlis, Nizar ;
Basu, Supratik ;
Nahi, Hareth ;
Hulin, Cyrille ;
Quach, Hang ;
Goldschmidt, Hartmut ;
O'Dwyer, Michael ;
Perrot, Aurore ;
Venner, Christopher P. ;
Weisel, Katja ;
Mace, Joseph R. ;
Raje, Noopur ;
Tiab, Mourad ;
Macro, Margaret ;
Frenzel, Laurent ;
Leleu, Xavier ;
Ahmadi, Tahamtan ;
Wang, Jianping ;
Van Rampelbergh, Rian ;
Uhlar, Clarissa M. ;
Tromp, Brenda ;
Delioukina, Maria ;
Vermeulen, Jessica ;
Usmani, Saad Z. .
LANCET ONCOLOGY, 2021, 22 (11) :1582-1596
[10]  
Field-Smith Antonia, 2006, Ther Clin Risk Manag, V2, P271, DOI 10.2147/tcrm.2006.2.3.271